Evidence map›Paper›PMID 28476871›Full record

Trial reportDiabetes care2017

Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.

William M Steinberg, John B Buse, Marie Louise Muus Ghorbani, David D Ørsted, Michael A Nauck, LEADER Steering Committee, LEADER Trial Investigators

2 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetes care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01179048. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01179048 phase3completed

A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

Ran2010Enrolled9,341Registered outcomes6Posted comparisons20ConditionsDiabetes, Diabetes Mellitus, Type 2Armsliraglutide, Placebo
PMID 29947247PMID 24176437PMID 30851070PMID 29760228PMID 30508430PMID 30566004PMID 30566006PMID 30260088PMID 29903847PMID 25656058PMID 25275271PMID 26855018other papers from this trial
Open the trial in the graph
NCT07617155 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Effects of GLP-1 Agonists on Prevention of HTG-Induced Acute Pancreatitis Recurrence: Protocol for a Randomized Clinical Trial

TypeinterventionalSponsorPeking Union Medical College HospitalRan2026 to 2028Enrolled396ConditionsHypertriglyceridemia Induced Acute Pancreatitis, Recurrent Acute Pancreatitis, Pancreatitis Relapsing, HypertriglyceridemiaArmsSemaglutide, Placebo (Normal Saline)
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

William M SteinbergGeorge Washington University Medical Center, Washington, DC wstein6905@aol.com.ORCID 0000-0002-6714-6974
John B BuseUniversity of North Carolina School of Medicine, Chapel Hill, NC.ORCID 0000-0002-9723-3876
Marie Louise Muus GhorbaniNovo Nordisk A/S, Bagsvaerd, Denmark.
David D ØrstedNovo Nordisk A/S, Bagsvaerd, Denmark.
Michael A NauckSt. Josef-Hospital, Ruhr University, Bochum, Germany.
LEADER Steering Committee
LEADER Trial Investigators
Novo Nordisk (Denmark) · DKGeorge Washington University · USSt. Josef-Hospital · DEUniversity of North Carolina at Chapel Hill · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate serum amylase and lipase levels and the rate of acute pancreatitis in patients with type 2 diabetes and high cardiovascular risk randomized to liraglutide or placebo and observed for 3.5-5.0 years. RESEARCH DESIGN AND

methodsA total of 9,340 patients with type 2 diabetes were randomized to either liraglutide or placebo (median observation time 3.84 years). Fasting serum lipase and amylase were monitored. Acute pancreatitis was adjudicated in a blinded manner.

resultsCompared with the placebo group, liraglutide-treated patients had increases in serum lipase and amylase of 28.0% and 7.0%, respectively. Levels were increased at 6 months and then remained stable. During the study, 18 (0.4% [1.1 events/1,000 patient-years of observation] [PYO]) liraglutide-treated and 23 (0.5% [1.7 events/1,000 PYO]) placebo patients had acute pancreatitis confirmed by adjudication. Most acute pancreatitis cases occurred ≥12 months after randomization. Liraglutide-treated patients with prior history of pancreatitis (

conclusionsIn a population with type 2 diabetes at high cardiovascular risk, there were numerically fewer events of acute pancreatitis among liraglutide-treated patients (regardless of previous history of pancreatitis) compared with the placebo group. Liraglutide was associated with increases in serum lipase and amylase, which were not predictive of an event of subsequent acute pancreatitis.

Indexed as

Acute DiseaseAmylasesCardiovascular DiseasesDiabetes Mellitus, Type 2Double-Blind MethodFemaleHumansHypoglycemic AgentsLipaseLiraglutideMaleMiddle AgedPancreatitisRisk FactorsAmylasesHypoglycemic AgentsLipaseLiraglutide

Identifiers

PMID28476871
OpenAlexW2611275678

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.